Why the study?
DOACs recently became a therapeutic option alongside parenteral anticoagulants for cancer-associated VTE, but the factors influencing physicians' choice between LMWH and DOACs were unclear.
Patient preferences and physician concerns regarding bleeding risk and oral intake are major factors influencing the choice between DOACs and LMWHs for cancer-associated VTE.
Answers are grounded in this paper and cite their sources.
Should not change cancer-VTE anticoagulant choice; leaves open how trials can embed preference and bleeding-risk factors to stay practice-relevant.
Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.
No takes yet. Share an insight, caveat, or question.
Matzdorff et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: